skip to main content

United Therapeutics Corporation To Present At The Jefferies 2015 Global Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 29, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Roger Jeffs, Ph.D., President and Co-Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Jefferies 2015 Global Healthcare Conference in New York City.

The presentation and the immediately following Q&A session will take place on Thursday, June 4, 2015, at 11:00 AM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events & Presentations" section. An archived, recorded version of the presentation and the Q&A session will be available approximately twenty-four hours after the Q&A session ends and can be accessed at the same location for 90 days. [uthr-g]

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-the-jefferies-2015-global-healthcare-conference-300090609.html

SOURCE United Therapeutics Corporation

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...
The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and...
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-treated patients with...
First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDASILVER SPRING, Md. & RESEARCH TRIANGLE PARK...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...
Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from TETON-1...